A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients

IntroductionChemotherapy-induced alopecia is one of the most common adverse events caused by conventional cytotoxic chemotherapy, yet there has been very little progress in the prevention or treatment of this side effect. Although this is not a life-threatening event, alopecia is very psychologically difficult for many women to manage. In order to improve the quality of life for these women, it is important to elucidate the molecular mechanisms of chemotherapy-induced alopecia and develop ways to effectively prevent and/or treat it. To identify the genetic risk factors associated with chemotherapy-induced alopecia, we conducted a genome-wide association study (GWAS) using DNA samples from breast cancer patients who were treated with chemotherapy.MethodsWe performed a case-control association study of 303 individuals who developed grade 2 alopecia, and compared them with 880 breast cancer patients who did not show hair loss after being treated with conventional chemotherapy. In addition, we separately analyzed a subset of patients who received specific combination therapies by GWASs and applied the weighted genetic risk scoring (wGRS) system to investigate the cumulative effects of the associated SNPs.ResultsWe identified an SNP significantly associated with drug-induced grade 2 alopecia (rs3820706 in CACNB4 (calcium channel voltage-dependent subunit beta 4) on 2q23, P = 8.13 × 10-9, OR = 3.71) and detected several SNPs that showed some suggestive associations by subgroup analyses. We also classified patients into four groups on the basis of wGRS analysis and found that patients who classified in the highest risk group showed 443 times higher risk of antimicrotubule agents-induced alopecia than the lowest risk group.ConclusionsOur study suggests several associated genes and should shed some light on the molecular mechanism of alopecia in chemotherapy-treated breast cancer patients and hopefully will contribute to development of interventions that will improve the quality of life (QOL) of cancer patients.

[1]  W. Gajewski,et al.  The use of minoxidil to attempt to prevent alopecia during chemotherapy for gynecologic malignancies. , 1991, European journal of gynaecological oncology.

[2]  S. Closs,et al.  Knowledge, expectations and experiences of patients receiving chemotherapy for breast cancer. , 1992, Scandinavian journal of caring sciences.

[3]  M. Duvic.  Chemotherapy-induced alopecia. , 1993, Southern medical journal.

[4]  B. Leone,et al.  Minoxidil (Mx) as a prophylaxis of doxorubicin--induced alopecia. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  T. G. Freedman,et al.  Social and cultural dimensions of hair loss in women treated for breast cancer. , 1994, Cancer nursing.

[6]  D. Clapham,et al.  Calcium signaling , 1995, Cell.

[7]  G. Hortobagyi,et al.  A randomized trial of minoxidil in chemotherapy-induced alopecia. , 1996, Journal of the American Academy of Dermatology.

[8]  J. Verweij,et al.  Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. , 1997, British Journal of Cancer.

[9]  V H Price,et al.  Treatment of hair loss. , 1999, The New England journal of medicine.

[10]  N. Tanaka,et al.  STAM2, a new member of the STAM family, binding to the Janus kinases , 2000, FEBS letters.

[11]  L. Rogers,et al.  Psychological sequelae and alopecia among women with cancer. , 2001, Cancer practice.

[12]  R Paus,et al.  Controls of hair follicle cycling. , 2001, Physiological reviews.

[13]  W. Birchmeier,et al.  β-Catenin Controls Hair Follicle Morphogenesis and Stem Cell Differentiation in the Skin , 2001, Cell.

[14]  D. Batchelor.  Hair and cancer chemotherapy: consequences and nursing care--a literature study. , 2001, European journal of cancer care.

[15]  Yusuke Nakamura,et al.  A high-throughput SNP typing system for genome-wide association studies , 2001, Journal of Human Genetics.

[16]  H. Asao,et al.  Signal-Transducing Adaptor Molecules STAM1 and STAM2 Are Required for T-Cell Development and Survival , 2002, Molecular and Cellular Biology.

[17]  J. Haerting,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.

[18]  U. Suter,et al.  E‐cadherin controls adherens junctions in the epidermis and the renewal of hair follicles , 2003, The EMBO journal.

[19]  W. Breed,et al.  Prevention of chemotherapy-induced hair loss by scalp cooling. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  K. Münstedt,et al.  Changes in self-concept and body image during alopecia induced cancer chemotherapy , 1997, Supportive Care in Cancer.

[21]  H. Manev,et al.  5-Lipoxygenase (ALOX5) and FLAP (ALOX5AP) gene polymorphisms as factors in vascular pathology and Alzheimer's disease. , 2006, Medical hypotheses.

[22]  J. Au,et al.  Protection Against Chemotherapy-Induced Alopecia , 2006, Pharmaceutical Research.

[23]  Yusuke Nakamura,et al.  The BioBank Japan Project. , 2007, Clinical advances in hematology & oncology : H&O.

[24]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[25]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[26]  Sarah E. Millar,et al.  Activation of β-catenin signaling programs embryonic epidermis to hair follicle fate , 2008, Development.

[27]  Kevin D Cooper,et al.  Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia. , 2009, The Journal of investigative dermatology.

[28]  Jing Cui,et al.  Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score , 2009, The Lancet Neurology.

[29]  Kai Sun,et al.  Association of three-gene interaction among MTHFR, ALOX5AP and NOTCH3 with thrombotic stroke: a multicenter case–control study , 2009, Human Genetics.

[30]  D. Ghersi,et al.  Single agent versus combination chemotherapy for metastatic breast cancer. , 2009, The Cochrane database of systematic reviews.

[31]  R. Trüeb.  Chemotherapy-induced alopecia. , 2009, Seminars in cutaneous medicine and surgery.

[32]  Annette Lee,et al.  Genome-wide association study in alopecia areata implicates both innate and adaptive immunity , 2010, Nature.

[33]  A. Lluch,et al.  Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. , 2010, Cancer treatment reviews.

[34]  Gui-Rong Li,et al.  Functional ion channels in stem cells. , 2011, World journal of stem cells.

[35]  E. Sprecher,et al.  P-cadherin regulates human hair growth and cycling via canonical Wnt signaling and transforming growth factor-β2. , 2012, The Journal of investigative dermatology.

[36]  Ralf Paus,et al.  Pathobiology of chemotherapy-induced hair loss. , 2013, The Lancet. Oncology.